Ajanta Pharma Boosts Profits with Strong US Generics Growth

Ajanta Pharma Ltd reported an 18.4% increase in consolidated net profit, driven by strong US generics revenue. The company achieved a net profit of Rs 266.7 crore in the fourth quarter. Consolidated revenue from operations reached Rs 1,421.64 crore, with significant growth in US and branded generics markets.

Ajanta Pharma Ltd has posted an impressive 18.4% rise in net profit for the fourth quarter, which ended on March 31. The increase is mainly attributed to robust revenue growth in the US generics market.

The company reported a consolidated net profit of Rs 266.7 crore, up from Rs 225.26 crore in the same quarter last year. Consolidated revenue from operations jumped to Rs 1,421.64 crore from Rs 1,170.41 crore, showcasing significant growth in both the US and branded generics markets in India, Asia, and Africa.

Notably, US generic revenue increased by 56%, reaching Rs 505 crore compared to Rs 325 crore in the previous year. Total expenses during the quarter rose to Rs 1,135.96 crore from Rs 919.11 crore. For the fiscal year, the net profit stood at Rs 1,056 crore, with an overall revenue of Rs 5,452.86 crore.